Karyopharm Therapeutics (NASDAQ:KPTI) has been assigned a $18.00 price target by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 71.27% from the company’s current price.
KPTI has been the topic of a number of other reports. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 31st. Royal Bank of Canada began coverage on Karyopharm Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $14.00 price objective on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Karyopharm Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.33.
Shares of Karyopharm Therapeutics (KPTI) opened at $10.51 on Tuesday. Karyopharm Therapeutics has a 1-year low of $7.48 and a 1-year high of $14.63.
In related news, SVP Christopher Brett Primiano sold 4,958 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $10.39, for a total transaction of $103,900.00. The disclosure for this sale can be found here. Insiders sold 23,340 shares of company stock valued at $255,380 in the last quarter. 14.71% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC raised its position in Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $136,000. Trexquant Investment LP bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $202,000. State of Wisconsin Investment Board bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $235,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Karyopharm Therapeutics by 26.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after acquiring an additional 5,586 shares during the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.